Molecular Breast Cancer Subtypes in Premenopausal and Postmenopausal African-American Women: Age-Specific Prevalence and Survival

Ihemelandu, Chukwuemeka; Leffall, LaSalle D.; DeWitty, Robert L.; Naab, Tammey; Mezghebe, Haile M.; Makambi, Kepher H.; Adams‐Campbell, Lucile L.; Frederick, Wayne

doi:10.1016/j.jss.2007.03.085

Cited by 133 publications

(105 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The frequencies of lymph node metastasis were not significantly different between the four subtypes in the current study, the positive lymph node rate was around 40% among the four subtypes. Other studies showed that patients with HER2+ subtype and triple-negative are more likely to be lymph node positive disease [11][12][13] , we did not find such associations in the current study, possibly due to different study populations or samples selected.…”

Section: Discussioncontrasting

confidence: 89%

Breast cancer subtypes and survival in Chinese women with operable primary breast cancer

Yao

Liu

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective: To investigate the associations between the different breast cancer subtypes and survival in Chinese women with operable primary breast cancer.Methods: A total of 1538 Chinese women with operable primary breast cancer were analyzed in this study, the median follow-up was 77 months. Estrogen receptor (ER), progesterone receptor (PR), and HER2 status were available for these patients.Results: Luminal A (ER+ and/or PR+, HER2-) had a favorable disease-free survival (DFS) and overall survival (OS) compared with other subtypes in the entire cohort. Using the luminal A as a reference, among the patients with lymph node positive disease, HER2+ (ER-, PR-, HER2+) had the worst DFS (hazard ratio, HR=1.80, 95% CI 1.11 to 2.91, P=0.017) and luminal B (ER+ and/or PR+, HER2+) had the worst OS (HR=2.27, 95% CI 1.50 to 3.45, P<0.001); among the patients with lymph node negative disease, triple-negative (ER-, PR-, HER2-) had the worst DFS (HR=2.21, 95% CI 1.43 to 3.41, P<0.001), whereas no significant difference in DFS between HER2+ and luminal B or luminal A was observed.Conclusion: As compared with luminal A, luminal B and HER2+ have the worst survival in patients with lymph node positive disease, but this is not the case in patients with lymph node negative disease; triple-negative subtype has a worse survival in both lymph node positive and lymph node negative patients.

show abstract

Section: Discussioncontrasting

confidence: 89%

Breast cancer subtypes and survival in Chinese women with operable primary breast cancer

Yao

Liu

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

show abstract

“…In addition, breast cancer in younger women may more often be of a basal cell-like subtype [6,7]. Diagnosing breast cancer in younger women is more difficult for several reasons.…”

Section: Introductionmentioning

confidence: 99%

Does Guideline-Adherent Therapy Improve the Outcome for Early-Onset Breast Cancer Patients?

Varga¹,

Wischnewsky

Atassi³

et al. 2010

Oncology

View full text Add to dashboard Cite

Background and Objective: Guidelines for the treatment of early-onset breast cancer have been proposed in several countries, but to date, their impact on outcomes is unverified. The objective of this study was to evaluate the association between guideline-adherent versus nonadherent treatment and recurrence-free survival (RFS) and overall survival (OAS) in early-onset breast cancer patients. Methods: A total of 1,778 patients were included in the study, of whom 111 were 35 years or younger and 1,667 were between 36 and 55 years. RFS and OAS were compared between the two groups, with respect to multiple parameters. All survival data were adjusted for tumor characteristics and analyzed with respect to guideline adherence according to the German Step 3 guidelines. Results: Statistically significant differences between the two groups (<35 years, 36–55 years) were observed with regard to breast surgery (p = 0.002) and hormone therapy (p = 0.006). Both groups were treated identically in terms of guideline adherence concerning axillary dissection (p = 0.9), radiation therapy (p = 0.7) and chemotherapy (p = 0.556). Young breast cancer patients whose treatment adhered to guideline recommendations had increased RFS and OAS [RFS: p = 0.030, hazard ratio (HR) 2.95, 95% confidence interval (CI) 1.11–7.83; OAS: p ≤ 0.001, HR 2.92, 95% CI 2.01–4.23]. Conclusion: Guideline-adherent treatment for early-onset breast cancer patients significantly improves OAS and RFS and should therefore be demanded for all patients.

show abstract

“…With the advances in molecular biological research, a more in-depth understanding of breast cancer has been developed. Nowadays, breast cancer can be generally classified into luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and triple negative breast cancer (TNBC) based on the presence or absence of the estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 (Ihemelandu et al, 2007;Muñoz et al, 2009;Wiechmann et al, 2009;Park et al, 2012). Breast cancer is a heterogeneous disease consisting of different molecular subtypes with different molecular biological characteristics and clinical behaviors.…”

Section: Introductionmentioning

confidence: 99%

Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification

et al. 2015

View full text Add to dashboard Cite

ABSTRACT. This study aimed to explore new opportunities for developing targeted therapy for triple-negative breast cancer (TNBC) by analyzing the significance and association between p53 and epidermal growth factor receptor (EGFR) expression in different molecular subtypes of breast cancer. The clinical and pathological data of 264 patients with breast cancer receiving surgery in our hospital from January 2012 to August 2013 were retrospectively analyzed. According to the expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), Ki-67, CK5/6, p53, and EGFR detected by immunohistochemical methods, breast cancer was divided into four molecular subtypes. Then, the expression of p53 and EGFR as well as their correlation in the different subtypes were determined. Among the four subtypes, luminal B breast cancer was the most common type. TNBC and HER2-enriched breast cancer had larger tumor sizes with higher expression of Ki-67 as compared with the luminal types. TNBC had a lower lymph node metastasis rate but 4283 p53 and EGFR expression in breast cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 4282-4290 (2015) higher CK5/6 and EGFR expression than the other three types. The expression of p53 was higher in luminal B, HER2-enriched, and triplenegative breast cancers, and this was positively correlated with the expression of EGFR in TNBC but not in the other subtypes. p53 and EGFR expression was positively correlated in TNBC, which enables us to explore the molecular biological characteristics of TNBC, so as to provide new ideas for the treatment of TNBC.

show abstract

Molecular Breast Cancer Subtypes in Premenopausal and Postmenopausal African-American Women: Age-Specific Prevalence and Survival

Cited by 133 publications

References 27 publications

Breast cancer subtypes and survival in Chinese women with operable primary breast cancer

Breast cancer subtypes and survival in Chinese women with operable primary breast cancer

Does Guideline-Adherent Therapy Improve the Outcome for Early-Onset Breast Cancer Patients?

Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification

Contact Info

Product

Resources

About